Biogen announced the European Commission, or EC, has authorized Skyclarys for the treatment of Friedreich’s ataxia, or FA, in adults and adolescents aged 16 years and older. Skyclarys is the first treatment approved within the European Union for this rare, genetic, progressive neurodegenerative disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
- Is BIIB a Buy, Before Earnings?
- Aptar Digital Health enters enterprise agreement with Biogen
- QQQ ETF Update, 2/1/2024
- William Blair biotech analyst to hold an analyst/industry conference call
